News

Pharmaceutical Product Development, LLC (PPD), is expanding its bioanalytical laboratory in Richmond, Virginia, enhancing its ability to provide industry-leading capabilities to meet…
Read More...

Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.…
Read More...

Cryoport, Inc. announced the launch of its Advanced Therapy Shipper product line for the regenerative medicine market. The Advanced Therapy Shipper guarantees each shipper has been used…
Read More...

Boehringer Ingelheim and Inflammasome Therapeutics announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal…
Read More...

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S jointly announced today that the MHLW of Japan approved Trintellix (vortioxetine) for the treatment of depression and depressed…
Read More...

Y-Trap, Inc. has signed a collaboration and license agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, for the exclusive development of multiple…
Read More...

The SanBio Group announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for SB623 cell therapy for the…
Read More...

Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, announced that it has entered into a research…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva (obinutuzumab) for adults with lupus nephritis. This…
Read More...

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclotide), a…
Read More...

Versantis, a clinical-stage biotech company developing disruptive therapies for rare liver and pediatric diseases, today announces the successful completion of an oversubscribed CHF 16…
Read More...

BioXcel Therapeutics, a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in…
Read More...

BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced that it has entered into a Development, Supply, Distribution Agreement with Avanos Medical. Under the…
Read More...

iBio, Inc. announced that it has entered into the initial Statement of Work under its Memorandum of Understanding with AzarGen Biotechnologies (Pty.) Ltd. Following iBio’s successful…
Read More...

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH),…
Read More...

Concert Pharmaceuticals announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of…
Read More...

Novartis, a leader reimagining rheumatology and immuno-dermatology, announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx (secukinumab) in…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted…
Read More...

Merck, known as MSD outside the United States and Canada, and Eisai announced that the U.S. Food and Drug Administration (FDA) approved the combination of KEYTRUDA, Merck’s anti-PD-1…
Read More...

AlivaMab Discovery Services, a company providing custom human therapeutic antibody drug discovery services using the AlivaMab Mouse, a best-in-class antibody discovery platform,…
Read More...